These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24866200)

  • 1. Cost of treatment in a US commercially insured, HIV-1-infected population.
    Solem CT; Snedecor SJ; Khachatryan A; Nedrow K; Tawadrous M; Chambers R; Haider S; Simpson K
    PLoS One; 2014; 9(5):e98152. PubMed ID: 24866200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
    Mauskopf J; Brogan A; Martin S; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():83-105. PubMed ID: 21182346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
    Brogan A; Mauskopf J; Talbird SE; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
    Hill AM; Gebo K; Hemmett L; Löthgren M; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():169-81. PubMed ID: 21182350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006.
    Krentz HB; Gill MJ
    HIV Med; 2008 Oct; 9(9):721-30. PubMed ID: 18643856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Annemans L; Löthgren M; Allegri G; Wyffels V; Hemmet L; Caekelbergh K; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():107-28. PubMed ID: 21182347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
    Ruof J; Dusek A; DeSpirito M; Demasi RA
    Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary costs of HIV healthcare in the HAART era.
    Gebo KA; Fleishman JA; Conviser R; Hellinger J; Hellinger FJ; Josephs JS; Keiser P; Gaist P; Moore RD;
    AIDS; 2010 Nov; 24(17):2705-15. PubMed ID: 20859193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting HIV care costs using CD4 counts from clinical trials.
    Hill A; Gebo K
    Am J Manag Care; 2007 Sep; 13(9):524-8. PubMed ID: 17803366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of HIV medical care in the era of highly active antiretroviral therapy.
    Gebo KA; Chaisson RE; Folkemer JG; Bartlett JG; Moore RD
    AIDS; 1999 May; 13(8):963-9. PubMed ID: 10371178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs.
    Zhou F; Kominski GF; Qian HZ; Wang J; Duan S; Guo Z; Zhao X
    BMC Med; 2011 Jan; 9():6. PubMed ID: 21241494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
    Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral Treatment Switching and Its Association With Economic Outcomes and Adverse Treatment Effects Among Commercially Insured and Medicaid-Enrolled Patients With HIV in the United States.
    Korsnes JS; Goodwin BB; Murray M; Candrilli SD
    Ann Pharmacother; 2016 Dec; 50(12):989-1000. PubMed ID: 27439947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost and incidence of prescribing errors among privately insured HIV patients.
    Hellinger FJ; Encinosa WE
    Pharmacoeconomics; 2010; 28(1):23-34. PubMed ID: 20014874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.
    Yazdanpanah Y; Goldie SJ; Losina E; Weinstein MC; Lebrun T; Paltiel AD; Seage GR; Leblanc G; Ajana F; Kimmel AD; Zhang H; Salamon R; Mouton Y; Freedberg KA
    Antivir Ther; 2002 Dec; 7(4):257-66. PubMed ID: 12553480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
    ; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
    Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of disease stage on direct medical costs of HIV management: a review of the international literature.
    Levy A; Johnston K; Annemans L; Tramarin A; Montaner J
    Pharmacoeconomics; 2010; 28 Suppl 1():35-47. PubMed ID: 21182342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.